Amyloid plaques are pathological hallmarks of Alzheimer’s Disease(AD)and biomarkers such as cerebrospinal fluid(CSF)β-amyloid 1–42(Aβ1-42)and amyloid positron emission tomographic(PET)imaging are important in diag...Amyloid plaques are pathological hallmarks of Alzheimer’s Disease(AD)and biomarkers such as cerebrospinal fluid(CSF)β-amyloid 1–42(Aβ1-42)and amyloid positron emission tomographic(PET)imaging are important in diagnosing amyloid pathology in vivo.ɛ4 allele of the Apolipoprotein E gene(ApoEɛ4),which is a major genetic risk factor for late onset AD,is an important genetic biomarker for AD pathophysiology.It has been shown that ApoEɛ4 is involved in Aβdeposition and formation of amyloid plaques.Studies have suggested the utility of peripheral blood ApoEɛ4 in AD diagnosis and risk assessment.However it is still a matter of debate whether ApoEɛ4 status would improve prediction of amyloid pathology and represent a cost-effective alternative to amyloid PET or CSF Aβin resource-limited settings in late onset AD.Recent research suggest that the mean prevalence of PET amyloid-positivity is 95%in ApoEɛ4-positive AD patients.This short review aims to provide an updated information on the relationship between ApoEɛ4 and amyloid biomarkers.展开更多
文摘Amyloid plaques are pathological hallmarks of Alzheimer’s Disease(AD)and biomarkers such as cerebrospinal fluid(CSF)β-amyloid 1–42(Aβ1-42)and amyloid positron emission tomographic(PET)imaging are important in diagnosing amyloid pathology in vivo.ɛ4 allele of the Apolipoprotein E gene(ApoEɛ4),which is a major genetic risk factor for late onset AD,is an important genetic biomarker for AD pathophysiology.It has been shown that ApoEɛ4 is involved in Aβdeposition and formation of amyloid plaques.Studies have suggested the utility of peripheral blood ApoEɛ4 in AD diagnosis and risk assessment.However it is still a matter of debate whether ApoEɛ4 status would improve prediction of amyloid pathology and represent a cost-effective alternative to amyloid PET or CSF Aβin resource-limited settings in late onset AD.Recent research suggest that the mean prevalence of PET amyloid-positivity is 95%in ApoEɛ4-positive AD patients.This short review aims to provide an updated information on the relationship between ApoEɛ4 and amyloid biomarkers.
